England, November 5th 2010 – An innovative new online “drug discovery on demand” platform has been launched by Molplex, a company specializing in products and services for the life sciences. Designed to help drug discovery groups working anywhere in the world, it aims to eliminate the high start-up costs and minimize the financial risks traditionally associated with inventing new medicines.

Molplex CEO David Leahy said: “As the pharmaceutical industry changes, a new ecosystem of small, flexible teams operating as “Micro Pharmas” is emerging. Molplex will provide the services they need to succeed at inventing better medicines at lower cost”.

The first version of the new Molplex system launched today offers free access to sophisticated drug design systems, high quality assay-ready stock chemicals and high content biological screening at www.molplex.com.

Editor’s Note

For more information contact: info@molplex.com, Tel: US:
1-408-905-2900 Europe: 44-191-211-1965 www.molplex.com

About Molplex
Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines by making sophisticated drug discovery information and laboratory systems available on-line and on demand. CEO David Leahy previously founded Cyprotex PLC, now the world’s largest ADME Tox service supplier. COO Dr Vladimir Sykora has extensive drug discovery experience and has developed sophisticated software systems for automated drug design. They are joined as VP for Asia-Pacific by Dr Brian O’Keeffe who has considerable commercial and senior management experience in drug development including President of Asia-Pacific for Quintiles.

Contact Details: i6, Charlotte Square, Newcastle Upon Tyne, England, NE1 4XF
info@molplex.com US: 1-408-905-2900 Europe: 44-191-211-1965